Combining BET inhibitors and PARP inhibitors might help patients resistant to chemotherapy, the study suggests.

LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor in HRD (homologous recombination deficiency) cancers. It has ...

Eikon Therapeutics, a company headed by the former Merck executive who steered the cancer drug Keytruda to FDA approval, has raised $350.7 million to support a pipeline that includes a lead drug ...

Results from the PAOLA-1 study showed that the PARP inhibitor drug significantly increased the time women lived without disease progression when added to the standard-of-care, Genentech’s ...

[48–50] Final data remain to be published. Table 1. Poly-(ADP-ribose) polymerase inhibitors in clinical studies. PARP inhibitor Number of completed or ongoing studies Type of studies completed ...

Calcineurin inhibitors are topical and systemic immunosuppressants. They can help treat atopic dermatitis and autoimmune disorders such as lupus and psoriasis. They may also help prevent organ ...

The synergy between AR and PARP inhibitors in TALAPRO-2 did not increase toxicity, unlike other combinations, supporting their broader application. Tanya B. Dorff, MD, medical oncologist and ...

And you are more likely to respond to a type of targeted drug called a PARP inhibitor. PARP is a protein found in our cells, it stands for poly-ADP ribose polymerase. It helps damaged cells to repair ...

According to recent market analysis, the global PARP inhibitor market, valued at USD 6,279.90 million in 2024, is set to witness exceptional growth, reaching USD 16,153.50 million by 2034. This ...

Immunotherapy uses our immune system to fight cancer. Targeted treatments include cancer growth blockers, drugs that block cancer blood vessel growth and PARP inhibitors. Immunotherapy treatments ...